H2-Q1 Inhibitors
Chemical inhibitors of H2-Q1 disrupt various stages of the protein's function, which is pivotal in the antigen presentation pathway. Concanamycin A and Bafilomycin A1 target the vacuolar-type H+-ATPase (V-ATPase), an enzyme complex that acidifies intracellular compartments like endosomes and lysosomes. The acidic environment is crucial for H2-Q1 to process antigens effectively. By inhibiting V-ATPase, these chemicals prevent the optimal acidification required for H2-Q1 function. Similarly, the ionophore Monensin alters intracellular ion gradients, impacting the maturation of endosomes and, consequently, the functionality of H2-Q1. The proton pump inhibitor Omeprazole also reduces vesicular acidification, thereby affecting H2-Q1 activity.
Proteasome inhibitors, such as Lactacystin, Epoxomicin, and MG-132, obstruct the proteolytic cleavage of proteins into peptides, which H2-Q1 then presents on the cell surface. This blockade results in a shortage of antigenic peptides for H2-Q1 to display, curtailing its role in immune surveillance. Leupeptin and E-64, as inhibitors of serine and cysteine proteases, respectively, hinder the breakdown of antigens into peptides suitable for loading onto H2-Q1. Z-VAD-FMK, while primarily a caspase inhibitor, can influence the processing of inflammatory cytokines, which might indirectly affect the functionality of H2-Q1. Collectively, these inhibitors compromise the integrity of the antigen processing and presentation pathway mediated by H2-Q1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
As a specific inhibitor of V-ATPases, Concanamycin A can lead to the inhibition of acidification within endosomes and lysosomes. H2-Q1 protein relies on the endosomal/lysosomal pathway for antigen processing; thus, the disruption of this pH-dependent pathway can inhibit the function of H2-Q1 in antigen presentation. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Similar to Concanamycin A, Bafilomycin A1 is also a specific inhibitor of V-ATPases. By inhibiting V-ATPase activity, Bafilomycin A1 prevents the acidification of vesicles, thus inhibiting the function of H2-Q1 in processing antigens for immune response due to the reliance of H2-Q1 on acidic vesicular environments for optimal activity. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that disrupts intracellular ion gradients, particularly sodium and hydrogen ions. The disruption in pH gradient affects the endosomal maturation and can inhibit the function of H2-Q1 by impairing the protein's ability to bind and present antigens properly. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome. Because H2-Q1 requires the degradation of proteins by the proteasome for antigen processing, lactacystin can inhibit the function of H2-Q1 by preventing the generation of peptide fragments necessary for binding to the H2-Q1 protein complex. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor. By inhibiting the proteasome, it prevents the degradation of proteins into peptides that H2-Q1 would normally present, thereby inhibiting H2-Q1's role in antigen presentation. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin is a reversible inhibitor of serine and cysteine proteases. It can inhibit the function of H2-Q1 by impeding the proteolytic processing of antigens, which is essential for the loading of antigenic peptides onto H2-Q1. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 is a potent inhibitor of cysteine proteases. The inhibition of these proteases can prevent the proper processing of antigenic peptides, thereby inhibiting the ability of H2-Q1 to present these peptides. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a reversible proteasome inhibitor. By preventing protein degradation, MG-132 inhibits the supply of peptides for H2-Q1, thus inhibiting its function in antigen processing and presentation. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Z-VAD-FMK is a pan-caspase inhibitor that can affect the processing of inflammatory cytokines. By modulating the immune response, this inhibitor can indirectly inhibit the function of H2-Q1 in immune surveillance. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Omeprazole, a proton pump inhibitor, can reduce the acidification inside vesicles, thus influencing the activity of enzymes involved in antigen processing. This reduction can inhibit the function of H2-Q1, which relies on the acidic environment for processing and presentation of antigens. | ||||||